Illinois Municipal Retirement Fund Makes New $2.18 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Illinois Municipal Retirement Fund bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 127,160 shares of the biotechnology company's stock, valued at approximately $2,181,000. Illinois Municipal Retirement Fund owned approximately 0.05% of ADMA Biologics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC grew its stake in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in shares of ADMA Biologics by 1.0% in the fourth quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company's stock valued at $2,304,000 after acquiring an additional 1,337 shares during the period. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics during the third quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. raised its position in ADMA Biologics by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after purchasing an additional 1,509 shares during the last quarter. Finally, Larson Financial Group LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth $31,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

ADMA Biologics Stock Performance

NASDAQ ADMA traded up $0.45 during trading hours on Tuesday, hitting $16.28. 3,835,382 shares of the stock were exchanged, compared to its average volume of 3,341,864. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market cap of $3.85 billion, a price-to-earnings ratio of 58.25 and a beta of 0.75. ADMA Biologics, Inc. has a 12-month low of $5.52 and a 12-month high of $23.64. The stock has a 50-day moving average of $16.69 and a 200 day moving average of $17.98.

Analyst Upgrades and Downgrades

ADMA has been the topic of several recent research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. Finally, HC Wainwright upped their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.